<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="164721">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01776697</url>
  </required_header>
  <id_info>
    <org_study_id>DW330SR-1001(Ver2.2)</org_study_id>
    <nct_id>NCT01776697</nct_id>
  </id_info>
  <brief_title>Phase 1 Study to Compare the Pharmacokinetic Characteristics and Food Effect of Pelubiprofen (30mg) Tablet IR TID and Pelubiprofen SR (as a Pelubiprofen 90 mg) Tablet QD in Healthy Subjects</brief_title>
  <official_title>A Randomized, Open-labeled, Comparative 3-way Crossover Study to Compare the Pharmacokinetic Characteristics and Food Effect of Pelubiprofen (30mg) Tablet IR TID and Pelubiprofen SR (as a Pelubiprofen 90 mg) Tablet QD in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewon Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewon Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <authority>South Korea: Korea Food and Drug Administration (KFDA)</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, open-labeled, comparative 3-way crossover study to compare the pharmacokinetic
      characteristics and food effect of pelubiprofen (30mg) tablet IR TID and pelubiprofen SR (as
      a pelubiprofen 90 mg) tablet QD in healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>N/A</study_design>
  <primary_outcome>
    <measure>AUC of pelubiprofen(30mg) tablet IR TID</measure>
    <time_frame>0, 1, 2, 8, 9, 15, 16, 22 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC of pelubiprofen SR (as a pelubiprofen 90 mg) tablet QD</measure>
    <time_frame>0, 1, 2, 8, 9, 15, 16, 22 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of pelubiprofen(30mg) tablet IR TID</measure>
    <time_frame>0, 1, 2, 8, 9, 15, 16, 22 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of pelubiprofen SR (as a pelubiprofen 90 mg) tablet QD</measure>
    <time_frame>0, 1, 2, 8, 9, 15, 16, 22 day</time_frame>
  </primary_outcome>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>pelubiprofen (30mg) tablet IR TID, fasting</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>pelubiprofen (30mg) tablet IR TID, fed</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>pelubiprofen SR (as a pelubiprofen 90 mg) tablet QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pelubiprofen (30mg) tablet IR</intervention_name>
    <arm_group_label>pelubiprofen (30mg) tablet IR TID, fasting</arm_group_label>
    <arm_group_label>pelubiprofen (30mg) tablet IR TID, fed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pelubiprofen SR (as a pelubiprofen 90 mg) tablet</intervention_name>
    <arm_group_label>pelubiprofen SR (as a pelubiprofen 90 mg) tablet QD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult Healthy males aged 20~45 years

          2. weight over 45 kg, ideal body weight Â±20%[Ideal weight] = [Height(cm)-100] X 0.9

          3. Subjects who voluntarily agreed with written consent

        Exclusion Criteria:

          1. Patients with acute disorder within 28 days before clinical trial drugs
             administration

          2. History of disorders(inflammatory GI tract disease, stomach ulcer, gastrectomy, liver
             disease) which can affect ADME of drugs

          3. Patients with active GI tract, cardiovascular, respiratory, renal, endocrinal,
             haematological, central nerval, psychiatric disease or malignant tumor
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 23, 2013</lastchanged_date>
  <firstreceived_date>January 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
